Core Viewpoint - The approval of GPN01530 by the FDA marks a significant step for the company in the global development of radiopharmaceuticals for cancer diagnosis and treatment [1] Group 1: Product Development and Approval - The company announced that its self-developed radiopharmaceutical GPN01530 has received FDA approval to conduct Phase I/II clinical trials for diagnosing solid tumors [1] - GPN01530 targets fibroblast activation protein (FAP) and is the first self-developed RDC product of the company to gain FDA approval for clinical research [1] - The successful approval of GPN01530 is seen as a crucial milestone in the company's international development and registration of radiopharmaceuticals [1] Group 2: Product Pipeline and Future Plans - The company has established a comprehensive layout in the radiopharmaceutical sector, covering research, production, distribution, and sales [2] - Currently, the company has 16 innovative products in the research and registration phase, targeting seven types of cancer, including liver cancer, prostate cancer, and brain cancer [2] - The company plans to continue strengthening its research and development in the radiopharmaceutical sector, aiming to enrich its product pipeline and form a cluster of anti-tumor diagnostic and therapeutic products centered around Yttrium-90 microsphere injection [2]
远大医药：自研创新药GPN01530在美国获批开展临床研究